This study will evaluate the long-term safety and efficacy of AXS-05 in subjects with Alzheimer's disease (AD) agitation.
This study is a multi-center trial consisting of an open-label segment of up to 52 weeks, followed by a double-blind, placebo-controlled, randomized withdrawal segment. Subjects participating in the randomized-withdrawal segment will be randomized in a 1:1 ratio either to continue to receive AXS-05 or switch to placebo, for up to 24 weeks.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
456
AXS-05 tablets, taken twice daily
Placebo tablets, taken twice daily
Long-term Safety
Incidence of treatment-emergent adverse events following dosing with AXS-05
Time frame: up to 76 weeks
Time to relapse of agitation symptoms
Time frame: up to 24 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Clinical Research Site
Peoria, Arizona, United States
Clinical Research Site
Tempe, Arizona, United States
Clinical Research Site
Long Beach, California, United States
Clinical Research Site
Santa Ana, California, United States
Clinical Research Site
Temecula, California, United States
Clinical Research Site
Walnut Creek, California, United States
Clinical Research Site
Bonita Springs, Florida, United States
Clinical Research Site
Brandon, Florida, United States
Clinical Research Site
Coral Springs, Florida, United States
Clinical Research Site
Greenacres City, Florida, United States
...and 37 more locations